The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): Preliminary results from the phase 1b study.
 
Zhaoyu Jin
Employment - FutureGen Biopharmaceutical
 
Yanqiao Zhang
No Relationships to Disclose
 
Funan Liu
No Relationships to Disclose
 
Shu Zhang
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Miao Zhang
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Junye Wang
No Relationships to Disclose
 
Yun Li
No Relationships to Disclose
 
Xiaochun Yang
Employment - FutureGen Biopharmaceutical
 
Yaping Yang
Employment - Futuregen
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)